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Objectives: Our objective was to evaluate factors associated with recurrence in patients with 027þ and
027e Clostridium difficile infection (CDI).
Methods: Patients with CDI observed between January and December 2014 in six hospitals were
consecutively included in the study. The 027 ribotype was deduced by the presence of tcdB, tcdB, cdt
genes and the deletion D117 in tcdC (Xpert® C. difficile/Epi). Recurrence was defined as a positive lab-
oratory test result for C. difficilemore than 14 days but within 8 weeks after the initial diagnosis date with
reappearance of symptoms. To identify factors associated with recurrence in 027þ and 027e CDI, a
multivariate analysis was performed in each patient group. Subdistributional hazard ratios (sHRs) and
95% confidence intervals (95%CIs) were calculated.
Results: Overall, 238 patients with 027þ CDI and 267 with 027e CDI were analysed. On multivariate
analysis metronidazole monotherapy (sHR 2.380, 95%CI 1.549e3.60, p <0.001) and immunosuppressive
treatment (sHR 3.116, 95%CI 1.906e5.090, p <0.001) were factors associated with recurrence in patients
with 027þ CDI. In this patient group, metronidazole monotherapy was independently associated with
recurrence in both mild/moderate (sHR 1.894, 95%CI 1.051e3.410, p 0.033) and severe CDI (sHR 2.476,
95%CI 1.281e4.790, p 0.007). Conversely, non-severe disease (sHR 3.704, 95%CI 1.437e9.524, p 0.007)
and absence of chronic renal failure (sHR 16.129, 95%CI 2.155e125.000, p 0.007) were associated with
recurrence in 027e CDI.
Conclusions: Compared to vancomycin, metronidazole monotherapy appears less effective in curing CDI
without relapse in the 027þ patient group, independently of disease severity.M. Falcone, Clin Microbiol
Infect 2018;▪:1
© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introductionectious Diseases, Department
Pisa, Italy.
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biology and Infectious Diseases. Pu
et al., Risk factors for recurre
ection (2018), https://doi.orgClostridium difficile infection (CDI) is the most common cause of
healthcare-associated diarrhoea [1]. It is associated with an
increased length of hospital stay, readmission and mortality rates,blished by Elsevier Ltd. All rights reserved.
nce in patients with Clostridium difficile infection due to 027 and non-
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rence occurs [2]. Unfortunately, a recurrence occurs in approxi-
mately 19e20% of patients following a first episode of CDI, and it
significantly increases the mortality rate [3,4]. Thus, the recent
development of new therapeutic agents aims to reduce the recur-
rence rate in patients with CDI [5,6].
The global incidence of CDI has markedly increased in the last
decades, and a rise in severe episodes has been reported worldwide
[7e9]. This phenomenon has been partially attributed to the
emergence of a hypervirulent strain, variously called North Amer-
ican pulsed-field gel electrophoresis type 1 (NAP1) strain, PCR
ribotype 027, or restriction endonuclease analysis (REA) group BI,
according to the detection method used [10,11]. Despite conflicting
data, an association between 027 strain and poor outcome has
recently been reported [12,13]. Moreover, infection by BI/NAP1/027
strain increases the risk of recurrence [14,15]. However, few studies
have examined risk factors for recurrence in patients with initial
infection due to a 027 strain in a non-epidemic setting.
Materials and methods
The aim of our study is to identify factors associated with
recurrence in patients with CDI due to presumptive 027 (027þ) and
non-027 (027e) strains.
Setting
This observational study was conducted between January and
December 2014 in the University Hospital Policlinico Umberto I e
‘Sapienza’ in Rome, which was designed as the coordinating centre
of the study; CDI episodes were collected from five other large
tertiary hospitals: San Giovanni Addolorata hospital Rome; Azienda
Ospedaliera Sant’Andrea e ‘Sapienza’ University, Rome; Policlinico
Tor vergata e ‘Tor Vergata’ University, Rome; Policlinico Gemelli e
Catholic University, Rome; and Santa Maria Goretti hospital e
‘Sapienza’ University Polo Pontino, Latina. The involved hospitals
care for a local population of 2.4 million people with a total number
of 4631 beds. The local ethics committee approved the study.
Patients
We included patients with a first episode of CDI that met the
definition criteria. CDI episodes occurring in all wards of hospital-
ization were included. We excluded from the study patients with
unavailable data from the first CDI episode [16]. CDI was defined as
(a) the presence of diarrhoea (passage of three or more unformed
stools in 24 consecutive hours) and (b) a stool test result positive
for the presence of toxigenic C. difficile or its toxins, or colonoscopic
or histopathological findings demonstrating pseudomembranous
colitis [17e20].
Data collection and study definitions
Based on records frommicrobiology laboratories of the involved
centres, all cases with diarrhoea with positive assay for C. difficile
were initially identified. The microbiological identification of
C. difficilewas performed in each hospital (six laboratories) by stool
specimen testing with the commercial methods, using enzyme
immunoassays (EIAs) combining detection of C. difficile glutamate
dehydrogenase (GDH) and toxin A/B antigens. Presumptive ribo-
type 027 was deducted by the Cepheid Xpert C. difficile/Epi assay,
which is amultiplex real-time polymerase chain reaction (PCR) that
detects tcdB, the binary toxin gene (cdt), and the tcdC gene deletion
at nt 117 (D117). Cases whose strain typing results were unavailable
were excluded from the study.Please cite this article in press as: Falcone M, et al., Risk factors for recurre
027 ribotypes, Clinical Microbiology and Infection (2018), https://doi.orgAll identified CDI cases subsequently underwent a full medical
record review to collect information on demographics, place of
acquisition, receipt of any immunosuppressive and antibiotic
therapy during 14 days prior to infection, and clinical comorbid-
ities. The Charlson comorbidity index was also calculated [21].
First episodes of CDI were classified as community-associated if
a positive specimen was collected in an outpatient setting or 3
calendar days after hospital admission with no documented over-
night stay in a healthcare facility (i.e., hospital or nursing home) in
the previous 12 weeks. All the other cases were defined as
healthcare-associated infections and were further classified into
three subgroups: community-onset healthcare-associated if a
positive specimen was collected in an outpatient setting or 3
calendar days after hospital admission from a private residence and
documented overnight stay in a healthcare-facility (i.e., hospital or
nursing home) in the previous 12 weeks; hospital-onset if a
C. difficile-positive specimen was collected >3 calendar days after
hospital admission or in a long-term acute-care hospital; nursing-
home onset if a positive specimen was collected in a nursing
home or from a nursing-home resident either in an outpatient
setting or within 3 days after hospital admission [1].
All CDI cases were followed up for at least 8 weeks after a first
episode of CDI with a site visit or, when that was not possible,
through phone contact. Cure was defined as resolution of symp-
toms without recurrence in the 8 weeks following the diagnosis.
Recurrent CDI was defined as another positive laboratory test result
for C. difficile more than 14 days but 56 days after the initial
diagnosis date in a patient with reappearance of symptoms [22].
Severity of CDI was defined according to criteria in the joint
practice guidelines of the Society for Healthcare Epidemiology of
America and the Infectious Diseases Society of America [18]. Pa-
tients with unexplained leucocytosis (white blood cell count
15,000/mL not attributable to other clinical conditions or comor-
bidities) or elevated serum creatinine level 1.5 times the baseline
value (defined as the mean serum creatinine value in the 90 days
before CDI) within 4 days of the CDI diagnosis datewere considered
to have severe CDI [20].
Therapy for the first CDI was coded in three categories: vanco-
mycin monotherapy, metronidazole monotherapy, and
vancomycinemetronidazole combination therapy. In order to
assess the effects of the vancomycin dosage, we also evaluated a
five-category variable in which vancomycin was separated in
standard and high dosages (vancomycin monotherapy standard
dosages, vancomycin monotherapy high dosages, metronidazole
monotherapy, metronidazole plus vancomycin standard dosages,
metronidazole plus vancomycin high dosages).Statistical analysis
Incidence of CDIwas expressed as cases per 10,000 patient-days.
Incidence of recurrencewas evaluated bymeans of Gray cumulative
incidence estimator, taking into account the competing risk of
death.
To evaluate differences between patients with CDI due to the
027 strain and those with episodes caused by non-027 strains, the
study populationwas divided into two study groups: 027þ CDI and
027e CDI.
Data are expressed as the mean ± standard deviation or median
(interquartile range, IQR) for continuousvariables, and thenumberof
cases (percentage) for categorical variables. All variables were tested
for normality using the non-parametric KolmogoroveSmirnov test.
Continuous variables were compared by Student t-test for inde-
pendent samples, for normally distributed variables, or by the
KruskaleWallis test in cases of variables with a skewed distribution.nce in patients with Clostridium difficile infection due to 027 and non-
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exact test when appropriate.
Since in our study an event (death) that precludes the occur-
rence of the event of interest (recurrence) was present, a competing
risk analysis was performed using the subdistribution hazard
model. Predictors of the first CDI recurrence were determined by
Fine and Gray regression models for subdistributional hazards in
each study group [23]. The final multivariate models were selected
as the model with the lowest Akaike information criterion values.
Variables associated with recurrence (p <0.05) and non-correlated
at the univariate analysis and those with clinical relevance were
considered for the multivariate model.
Subdistributional hazard ratios (sHR) and 95%CIs were calcu-
lated to evaluate the strength of any association.
All data were statistically analysed using two commercially
available statistical software packages (SPSS, version 20.0; SPSS
Inc., Chicago, IL and R, version 3.4.2; R development core team,
Wien, Austria). All tests were two-tailed, and a p value of 0.05 was
considered statistically significant.
Results
From January to December 2014, 717 episodes of CDI were
observed. CDI incidence was 4.2 cases/10,000 patient-days during
the study period. Table S-1 shows CDI incidence for each hospital.
No clusters were observed during the study period.
A diagram describing the study flow is shown in Fig. 1. Strain
typing results were available for 563 of 717 total CDI cases identi-
fied in the study period; of these, 238 patients with a documented
first episode of 027 CDI constituted the final group of 027þ CDI. The
proportion of 027þ CDI was 49.4% in the Policlinico Umberto I
hospital, 51.2% in the Torvergata University, 42.5% in the Sant’An-
drea hospital, 41.7% in the Catholic University and 64.7% in the
Santa Maria Goretti hospital. Conversely, 267 patients constituted
the final group of 027e CDI.
Table 1 shows the comparison between 027þ and 027e groups.
Overall, 48 (20.2%) patients with 027þ CDI and 15 (5.6%) patientsFig. 1. Study flow chart. CDI, Cl
Please cite this article in press as: Falcone M, et al., Risk factors for recurre
027 ribotypes, Clinical Microbiology and Infection (2018), https://doi.orgwith 027e CDI died during the 30 days after CDI diagnosis. The
crude recurrence rate in the entire population was 20% (101 cases).
The length of hospital stay was higher in patients in whom a
recurrence developed (36 (IQR 32e59) days) than in those who did
not (31.5 (IQR 20e37) days, p <0.001). Compared to patients with
CDI caused by non-027 strains, those with presumptive 027 infec-
tion had significantly higher crude recurrence rates (30.3% versus
10.9%, p <0.001). Taking into account the competing risk of death,
the recurrence rate among patients with 027þ and 027e CDI were
48.3% and 38.3%, respectively (p <0.001).
Table 2 shows the comparison of patients with recurrence and
those who were cured after the first CDI, according to the pre-
sumptive ribotype. The majority of recurrence episodes occurred
during hospitalization in both the 027þ group (84.5%) and 027e
group (82.8%). The group of patients treated with vancomycin plus
metronidazole therapy had the lowest rate of recurrence (7.7% in
027þ CDI and no recurrence in 027e CDI). Baseline characteristics
of these patients are shown in the Supplementary material Table S-
2.
As described in Table 3, on multivariate analysis the use of
metronidazole monotherapy compared to vancomycin (sHR
2.380, 95%CI 1.549e3.60, p <0.001) and the receipt of immuno-
suppressive treatment (sHR 3.116, 95%CI 1.906e5.090, p <0.001)
were factors independently associated with recurrence in pa-
tients with 027þ CDI. This result was confirmed also when we
considered five possible different treatments (low-dose vanco-
mycin, high-dose vancomycin, metronidazole monotherapy, low-
dose vancomycin plus metronidazole, high-dose vancomycin
plus metronidazole), with an sHR of 2.69 (95%CI 1.00e7.27, p
0.01) for metronidazole monotherapy. Conversely, as shown in
Table 4, on multivariate analysis lack of chronic renal failure (sHR
16.129, 95%CI 2.155e125.000, p 0.007) and non-severe CDI (sHR
3.704, 95%CI 1.437e9.524, p 0.007) were factors associated with
recurrence in patients with CDI due to non-027 strains.
Conversely, metronidazole monotherapy was not associated with
recurrence in this patient group (sHR 1.896, 95%CI 0.974e3.690, p
0.060).ostridium difficile infection.
nce in patients with Clostridium difficile infection due to 027 and non-
/10.1016/j.cmi.2018.06.020
Table 1
Comparison of baseline characteristics, disease severity, and treatment of patients with first infection due to 027 and non-027 Clostridium difficile strains
Characteristic 027þ n ¼ 238 027e n ¼ 267 p value
Demographics:
Male sex 128 (53.8%) 117 (43.8%) 0.025
Age in years (IQR) 72 (65e81) 72 (65e81) 0.809
Ward of hospitalization:
Internal Medicine 206 (86.6%) 246 (92.1%) 0.041
Surgery 26 (10.9%) 19 (7.1%) 0.134
ICU 6 (2.5%) 2 (0.7%) 0.111
Place of acquisition:
Community-associated 24 (10.1%) 17 (6.4%) 0.127
Healthcare-associated
Community onset healthcare-associated 26 (10.9%) 42 (15.7%) 0.114
Hospital onset 114 (47.9%) 159 (59.6%) 0.009
Nursing-home onset 74 (31.1%) 49 (18.4%) 0.001
Charlson comorbidity index:
Median (IQR) 7 (3e7) 7 (3e7) 0.912
Other ongoing conditions:
Diabetes 130 (54.6%) 137 (51.3%) 0.457
Cardiovascular disease 141 (59.2%) 155 (58.1%) 0.786
Chronic renal failure 105 (44.1%) 107 (40.1%) 0.358
COPD 117 (49.2%) 123 (46.1%) 0.487
Liver disease 10 (4.2%) 21 (7.9%) 0.087
IBD 4 (1.7%) 13 (4.9%) 0.047
Medications during 14 days prior to infection:
Any immunusuppressive treatment 101 (42.4%) 104 (38.9%) 0.426
Any antibiotic 124 (46.4%) 207 (77.5%) 0.866
Medication during the CDI episodes:
Concomitant use of PPI 194 (81.5%) 222 (83.1%) 0.631
Concomitant antibiotic therapy 92 (38.7%) 124 (46.4%) 0.077
Severe CDIa 124 (52.1%) 97 (36.3%) <0.001
Treatment of first CDI episode:
Vancomycin monotherapy 133 (55.9%) 194 (72.7%) <0.001
Metronidazole monotherapy 66 (27.7%) 38 (14.2%) <0.001
Vancomycin þ metronidazole 39 (16.4%) 35 (16.1%) 0.298
Vancomycin >500 mg/day 110 (46.2%) 56 (21%) <0.001
Recurrence 72 (30.3%) 29 (10.9%) <0.001
14-day mortality 20 (8.4%) 8 (3%) 0.008
30-day mortality 48 (20.2%) 15 (5.6%) <0.001
Statistical significant variables (p 0.05) were highlighted in bold. CDI, Clostridium difficile infection; COPD, chronic obstructive pulmonary disease; IBD, inflammatory
bowel disease; ICU, intensive care unit; IQR, interquartile range; PPI, protonic pump inhibitors.
a Severe CDI disease was defined as development of ileus, toxic megacolon, or pseudomembranous colitis within 5 days of the positive C. difficile stool specimen, or
unexplained serum white blood count 15,000 cells/mm3, or a serum creatinine level 1.5 times the premorbid level within 1 calendar day of collection of the stool
specimen.
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associated with recurrence in the 027þ group, according to disease
severity. Metronidazole monotherapy was an independent risk
factor for recurrence in both mild/moderate CDI (sHR 1.894, 95%CI
1.052e3.410, p 0.033) and severe CDI (sHR 2.476, 95%CI
1.281e4.790, p 0.007).
Discussion
To our knowledge this is the first study evaluating risk factors for
recurrence among patients with CDI due to 027 and non-027
strains in a large cohort of patients. The key message of our study
is that metronidazole monotherapy is associated with a high risk of
recurrence in patients with the first episode of CDI caused by the
027 strain, in both mild to moderate and severe cases. Instead, the
initial choice of therapy (metronidazole or vancomycin) was not
significantly associated with recurrence of CDI caused by non-027
strains.
Together with vancomycin, metronidazole has been considered
the cornerstone of antibiotic treatment for CDI [19,20]. From the
early 1980s, vancomycin became the drug of choice for treating CDI,
especially because of its poor absorption from the intestinal tract
[24]. Subsequently, with increasing concern for the development of
vancomycin-resistant enterococci with oral vancomycin, the use ofPlease cite this article in press as: Falcone M, et al., Risk factors for recurre
027 ribotypes, Clinical Microbiology and Infection (2018), https://doi.orgmetronidazole quickly increased. Furthermore, several trials found
that metronidazole and vancomycin are equally effective for the
treatment of mild CDI, but that vancomycin is superior for treating
patients with severe CDI [25,26]. Recent updates of treatment al-
gorithms for CDI reconsidered the use of metronidazole as first-line
therapy since it appears to be less efficacious than vancomycin in
inducing clinical cure, especially for severe infections [27]. Based on
these observations, current guidelines from the Infectious Diseases
Society of America revised treatment recommendations for CDI and
stated that either vancomycin or fidaxomicin is recommended over
metronidazole for an initial episode of CDI [18]. Oral metronidazole
is now recommended in settings where access to vancomycin or
fidaxomicin is limited, for an initial episode of non-severe CDI only,
while the combination of oral vancomycin and intravenous metro-
nidazole should be used in cases of fulminant CDI, particularly if
ileus is present [18]. Other studies have reported a lower incidence
of recurrence in patients with 027e CDI treated with a prolonged
and pulsed oral vancomycin regimen [28], and the emergence of
some Clostridium difficile isolates (other than 027 strains) showing
reduced susceptibility to metronidazole has been described [29].
Accordingly, with these recent recommendations, our results sug-
gest that the use of metronidazole as first-line therapy should be
discouraged in all cases of presumptive or documented CDI caused
by a 027 ribotype, independently of disease severity.nce in patients with Clostridium difficile infection due to 027 and non-
/10.1016/j.cmi.2018.06.020
Table 2
Comparison of patients in whom infection recurred or not after the first Clostridium difficile infection, stratified for presumed ribotype
Characteristic 027þ (n ¼ 238) 027e (n ¼ 267)
First recurrence n ¼ 72 (%) Cure n ¼ 166 (%) p value First recurrence n ¼ 29 (%) Cure n ¼ 238 (%) p value
Demographics:
Male sex 41 (56.9%) 87 (52.4%) 0.519 14 (48.3%) 103 (43.3%) 0.609
Age (years): median (IQR) 72 (65e82) 72 (65e81) 0.651 72 (65e72) 72 (65e82.5) 0.088
Ward of hospitalization:
Internal medicine 62 (86.1%) 144 (86.7%) 0.895 22 (75.9%) 224 (94.1%) 0.001
Surgery 10 (13.9%) 16 (9.6%) 0.334 5 (17.2%) 14 (5.9%) 0.025
ICU 0 6 (3.6%) 0.102 2 (6.9%) 0 <0.001
Place of acquisition:
Community-associated 9 (12.5%) 15 (9%) 0.415 1 (3.4%) 16 (6.7%) 0.495
Healthcare-associated
Community onset healthcare-associated 3 (4.2%) 23 (13.9%) 0.028 11 (37.9%) 31 (13%) 0.001
Hospital onset 19 (26.4%) 95 (57.2%) <0.001 12 (41.4%) 147 (61.8%) 0.035
Nursing-home onset 41 (56.9%) 33 (19.9%) <0.001 5 (17.2%) 44 (18.5%) 0.870
Charlson comorbidity index:
Median (IQR) 7 (6e7) 5 (2e7) <0.001 7 (3e7) 7 (2e7) 0.901
Other ongoing conditions:
Diabetes 57 (79.2%) 73 (44%) <0.001 17 (58.6%) 120 (50.4%) 0.404
Cardiovascular disease 45 (62.5%) 96 (57.8%) 0.501 13 (44.8%) 142 (59.7%) 0.126
Chronic renal failure 46 (63.9%) 59 (35.5%) <0.001 1 (3.4%) 106 (44.5%) <0.001
COPD 48 (66.7%) 69 (41.6%) <0.001 14 (48.3%) 109 (45.8%) 0.800
Liver disease 3 (4.2%) 7 (4.2%) 0.986 0 21 (8.8%) 0.096
IBD 1 (1.4%) 3 (1.8%) 0.818 0 13 (5.5%) 0.197
Medications during 14 days prior to infection:
Any immunosuppressive treatment 52 (72.2%) 49 (29.5%) <0.001 6 (20.7%) 98 (41.2%) 0.033
Any antibiotic 56 (77.8%) 130 (78.3%) 0.927 26 (89.7%) 181 (76.1%) 0.097
Medication during the CDI episodes:
Concomitant use of PPI 62 (86.1%) 132 (79.5%) 0.229 24 (82.8%) 198 (83.2%) 0.953
Concomitant antibiotic therapy 31 (43.1%) 61 (36.7%) 0.359 12 (41.4%) 112 (47.1%) 0.563
Severe CDIa 34 (47.2%) 90 (54.2%) 0.321 5 (17.2%) 92 (38.7%) 0.024
Treatment of first CDI episode: <0.001 0.038
Vancomycin monotherapy 35 (48.6%) 98 (59%) 22 (75.9%) 172 (72.3%)
Metronidazole monotherapy 34 (47.2%) 32 (19.3%) 7 (24.1%) 31 (13%)
Vancomycin þ metronidazole 3 (4.2%) 36 (21.7%) 0 35 (14.7%)
Vancomycin >500 mg/day 29 (40.3%) 81 (48.8%) 0.226 4 (13.8%) 52 (21.8%) 0.314
Statistical significant variables (p  0.05) were highlighted in bold. CDI, Clostridium difficile infection; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel
disease; ICU, intensive care unit; IQR, interquartile range; PPI, protonic pump inhibitors.
a Severe CDI disease was defined as development of ileus, toxic megacolon, or pseudomembranous colitis within 5 days of the positive C. difficile stool specimen, or un-
explained serum white blood count 15,000 cells/mm3, or a serum creatinine level 1.5 times the premorbid level within 1 calendar day of collection of the stool specimen.
Table 4
Multivariate analysis of risk factors for recurrence among patients with Clostridium difficile infection (CDI) due to non-027 strains
Multivariate analysis
sHR 95.0%CI p value
Lower Upper
Therapy for first CDI (vancomycin as reference variable):
Metronidazole monotherapy versus vancomycin monotherapy 1.896 0.974 3.690 0.060
Metronidazole þ vancomycin versus vancomycin monotherapy e e e e
Non-severe CDI 3.704 1.437 9.524 0.007
Absence of chronic renal failure 16.129 2.155 125.000 0.007
Statistical significant variables (p  0.05) were highlighted in bold. sHR, subdistributional hazard ratio.
Table 3
Multivariate analysis of risk factors for recurrence among patients with 027 Clostridium difficile infection (CDI)
Multivariate analysis
sHR 95.0%CI p value
Lower Upper
Therapy for first CDI (vancomycin as reference variable):
Metronidazole monotherapy versus vancomycin monotherapy 2.380 1.549 3.650 <0.001
Metronidazole þ vancomycin versus vancomycin monotherapy 0.349 0.105 1.150 0.084
Any immunosuppressive therapy 3.116 1.906 5.090 <0.001
Statistical significant variables (p  0.05) were highlighted in bold. sHR, subdistributional hazard ratio.
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Table 5
Multivariate analysis of factors associated with recurrence in patients with presumed 027 Clostridium difficile infection (CDI) according to disease severity
Mild/moderate disease (n¼114) Severe disease (n¼124)
sHR 95.0%CI p sHR 95.0%CI p value
Lower Upper Lower Upper
Any immunusuppressive treatment 2.375 1.294 4.360 0.005 1.879 1.183 19.640 0.008
Treatment of first CDI:
Vancomycin monotherapy Refa Refa Refa 0.033 Refa Refa Refa 0.007
Metronidazole monotherapy 1.894 1.051 3.410 0.210 2.476 1.281 4.790 0.250
Vancomycin þ metronidazole 0.378 0.083 1.730 0.302 0.040 2.280
Statistical significant variables (p  0.05) were highlighted in bold. sHR, subdistributional hazard ratio.
a All variables have been tested versus vancomycin (vancomycin monotherapy as reference variable).
M. Falcone et al. / Clinical Microbiology and Infection xxx (2018) 1e76Of importance, a very low risk of recurrence has been observed
in patients treated with combination therapy (vancomycin plus
metronidazole). However, probably due to the small number of
patients in this category, combination therapy was not a protective
factor for recurrence at multivariate analysis in both 027þ and
027e groups. Thus, the strategy of a combination therapy (adopted
more frequently in two study centres, Policlinico Torvergata and
Policlinico Gemelli) should be considered, especially in more
compromised patients [18].
Our study has some strengths and several limitations. The po-
tential limitations are the following. (a) It is an observational study.
(b) Presumptive ribotyping was performed in the majority (about
80%) but not all CDI cases. (c) the RT-PCR method used (Xpert
C. difficile Epi assay; Cepheid) allows a presumptive identification of
ribotype; the standard toxigenic cultures were not clinically prac-
tical because of slow turnaround times, and it has been reported
that Xpert, C.difficile Epi displays sensitivities and specificities of
96.6e99.7% and 93.0e98.6%, respectively [30,31]. (d) Since the
isolates from recurrence were not re-tested by Xpert, C.difficile Epi
or other methods, we were not able to distinguish with certainty a
recurrence from a reinfection. (e) All cases were collected in central
Italy, a region of high prevalence of the 027 strain [32]. (f) The
adjusted HR for metronidazole monotherapy and recurrence in the
027e patient group approached statistical significance, but due to
the small numbers of patients we were not able to perform a
subgroup analysis of severe and non-severe CDI in this patient
group.
The strengths of our study are its multicentre design, the large
sample size, the accuracy of data collection, and the fact that this is
the largest study to date to evaluate risk factors for recurrence
among the specific population of 027e CDI in a real-world setting.
Furthermore, all cases were collected in the absence of a recognized
epidemic outbreak.
We conclude that patients affected by 027þ CDI have some
peculiar risk factors for recurrence. Compared to vancomycin,
metronidazole monotherapy is a major risk factor for recurrence in
patients with CDI due to the 027 strain, independently of disease
severity. Thus, vancomycin instead of metronidazole seems to be
the drug of choice in all patients with a first episode of CDI, espe-
cially in those with infection due to the 027 strain. Based on these
observations, we suggest that ribotyping to identify 027 or non-027
strains should be performed in clinical practice to guide therapy.Transparency declaration
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